Immunomodulatory agents in myelofibrosis

Bibliography

• Agrawal M, Garg RJ, Cortes J, Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 2011;117:662-76
   PubMed Web of Science ®Google Scholar
• Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 2011;12:1597-611
   PubMed Web of Science ®Google Scholar
• Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007;13:377-83
   PubMed Web of Science ®Google Scholar
• Brecqueville M, Rey J, Bertucci F, Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012 Apr 9. doi: 10.1002/gcc.21960. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171-91
   PubMed Web of Science ®Google Scholar
• Grand FH, Hidalgo-Curtis CE, Ernst T, Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92
   PubMed Web of Science ®Google Scholar
• Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs 2009;14:471-9
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
   PubMed Web of Science ®Google Scholar
• Arora B, Sirhan S, Hoyer JD, Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005;128:42-8
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li CY, Ketterling RP, Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105:973-7
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma 2011;52:560-6
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 2007;8:497-509
   PubMed Web of Science ®Google Scholar
• Martyre MC, Magdelenat H, Bryckaert MC, Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991;77:80-6
   PubMed Web of Science ®Google Scholar
• Martyre MC, Romquin N, Le Bousse-Kerdiles MC, Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16
   PubMed Web of Science ®Google Scholar
• Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996;88:4534-46
   PubMed Web of Science ®Google Scholar
• Pardanani A, Begna K, Finke C, Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011;86:343-5
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-63
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Visani G, Pileri SA, Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16:1609-14
   PubMed Web of Science ®Google Scholar
• Mesa RA, Hanson CA, Rajkumar SV, Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-80
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
   PubMed Web of Science ®Google Scholar
• Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-41
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cortes J, Verstovsek S, Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-64
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson PG, Anderson KC. Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs 2006;15:171-9
   PubMed Web of Science ®Google Scholar
• Galili N, Raza A. Immunomodulatory drugs in myelodysplastic syndromes. Expert Opin Investig Drugs 2006;15:805-13
   PubMedGoogle Scholar
• Corti A, Giovannini M, Belli C, Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: focus on TLR9 Agonists, IMiDs and NGR-TNF. J Oncol 2010;2010:732680. Epub 2010 Jun 3
   PubMedGoogle Scholar
• Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-52
   PubMed Web of Science ®Google Scholar
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol 2005;42:S3-8
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69:7347-56
   PubMed Web of Science ®Google Scholar
• Moutouh-de Parseval LA, Verhelle D, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008;118:248-58
   PubMed Web of Science ®Google Scholar
• Elliott MA, Mesa RA, Li CY, Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288-96
   PubMed Web of Science ®Google Scholar
• Abgrall JF, Guibaud I, Bastie JN, Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006;91:1027-32
   PubMed Web of Science ®Google Scholar
• Barosi G, Elliott M, Canepa L, Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301-7
   PubMed Web of Science ®Google Scholar
• Thomas DA, Giles FJ, Albitar M, Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006;106:1974-84
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Kantarjian H, Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118:899-902
   PubMed Web of Science ®Google Scholar
• Marchetti M, Barosi G, Balestri F, Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004;22:424-31
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 2000;96:4007
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737-40
   PubMed Web of Science ®Google Scholar
• Begna KH, Mesa RA, Pardanani A, A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-4
   PubMed Web of Science ®Google Scholar
• Begna KH, Pardanani A, Mesa R, Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012;87:66-8
   PubMed Web of Science ®Google Scholar
• Thapaliya P, Tefferi A, Pardanani A, International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol 2011;86:96-8
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Manshouri T, Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-6
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yao X, Cripe LD, Lenalidomide and prednisone for myelofibrosis: eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436-8
   PubMed Web of Science ®Google Scholar
• Tefferi A, Verstovsek S, Barosi G, Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9
   PubMed Web of Science ®Google Scholar
• Ferguson GD, Jensen-Pergakes K, Wilkey C, Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 2007;27:210-20
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119:2721-30. Epub 2012 Jan 25
   PubMed Web of Science ®Google Scholar
• Tefferi A. How I treat myelofibrosis. Blood 2011;17:3494-504
   Google Scholar
• Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta 2007;1773:1572-82
   PubMed Web of Science ®Google Scholar
• Siatecka M, Bieker JJ. The multifunctional role of EKLF/KLF1 during erythropoiesis. Blood 2011;118:2044-54
   PubMed Web of Science ®Google Scholar
• Sekeres MA, List AF, Cuthbertson D, Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010;28:2253-8
   PubMed Web of Science ®Google Scholar
• Schmitt S, Ho AD, Goldschmidt H. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Onkologie 2010;33:183-6
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A, Lim KH, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-11
   PubMed Web of Science ®Google Scholar
• Carbuccia N, Murati A, Trouplin V, Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-6
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-70
   PubMed Web of Science ®Google Scholar
• Oh ST, Simonds EF, Jones C, Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988-92
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-6
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Biamonte F, Score J, EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011;118:5227-34
   PubMed Web of Science ®Google Scholar
• Stein BL, Williams DM, O'Keefe C, Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011;96:1462-9
   PubMed Web of Science ®Google Scholar
• Mesa RA, Pardanani AD, Hussein K, Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010;85(2):129-30
   PubMed Web of Science ®Google Scholar